

Carel Le Roux

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/249391/carel-le-roux-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

382
papers

17,793
citations

62
h-index

124
g-index

411
ext. papers

20,744
ext. citations

6.3
avg, IF

6.93
L-index

#	Paper	IF	Citations
382	Myokines in Appetite Control and Energy Balance 2022 , 1, 26-47		0
381	Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function.. <i>Journal of Experimental Medicine</i> , 2022 , 219,	16.6	2
380	Urinary Metabolomic Changes Accompanying Albuminuria Remission following Gastric Bypass Surgery for Type 2 Diabetic Kidney Disease.. <i>Metabolites</i> , 2022 , 12, 139	5.6	1
379	Ciliary neurotrophic factor is increased in the plasma of patients with obesity and its levels correlate with diabetes and inflammation indices.. <i>Scientific Reports</i> , 2022 , 12, 8331	4.9	
378	Can Weight Loss Improve the Cardiovascular Outcomes of Patients with Obesity and Obstructive Sleep Apnea?. <i>Hearts</i> , 2022 , 3, 54-65	0.6	0
377	Does Bypass of the Proximal Small Intestine Impact Food Intake, Preference, and Taste Function in Humans? An Experimental Medicine Study Using the Duodenal-jejunal Bypass Liner. <i>Nutrients</i> , 2022 , 14, 2141	6.7	0
376	The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. <i>Nutrients</i> , 2022 , 14, 2217	6.7	0
375	The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. <i>EclinicalMedicine</i> , 2022 , 49, 101436	11.3	1
374	Mechanisms of Action of Different Bariatric Surgical Procedures 2021 , 1-14		
373	Medications Activating Tubular Fatty Acid Oxidation Enhance the Protective Effects of Roux-en-Y Gastric Bypass Surgery in a Rat Model of Early Diabetic Kidney Disease.. <i>Frontiers in Endocrinology</i> , 2021 , 12, 757228	5.7	2
372	Protocol for a preclinical systematic review and meta-analysis of pharmacological targeting of peroxisome proliferator-activated receptors in experimental renal injury. <i>BMJ Open Science</i> , 2021 , 5, e100240	4.6	3
371	Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. <i>Lancet, The</i> , 2021 ,	40	13
370	Metabolic syndrome is associated with prostate enlargement: a systematic review, meta-analysis, and meta-regression on patients with lower urinary tract symptom factors.. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021 , 12, 20420188211066210	4.5	0
369	Concept of Metabolic Surgery 2021 , 1-7		
368	Effects of glucagon-like peptide-1 receptor agonists on histopathological and secondary biomarkers of non-alcoholic steatohepatitis: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	1
367	Meal Patterns and Food Choices of Female Rats Fed a Cafeteria-Style Diet Are Altered by Gastric Bypass Surgery. <i>Nutrients</i> , 2021 , 13,	6.7	2
366	A Comparison of Total Food Intake at a Personalised Buffet in People with Obesity, before and 24 Months after Roux-en-Y-Gastric Bypass Surgery. <i>Nutrients</i> , 2021 , 13,	6.7	3

365	The Impact of CKD on Perioperative Risk and Mortality after Bariatric Surgery.. <i>Kidney360</i> , 2021 , 2, 236-244	1
364	Impact of Metabolic Surgery on Renal Injury in Pre-Clinical Models of Diabetic Kidney Disease. <i>Nephron</i> , 2021 , 145, 585-594	3.3 3
363	Bariatric surgery in the treatment of patients with obesity and type 1 diabetes: A retrospective study of clinical data. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1562-1570	6.7 3
362	Factors Associated with Favorable Changes in Food Preferences After Bariatric Surgery. <i>Obesity Surgery</i> , 2021 , 31, 3514-3524	3.7 6
361	Clinical Impact of Liraglutide as a Treatment of Obesity. <i>Clinical Pharmacology: Advances and Applications</i> , 2021 , 13, 53-60	1.5 4
360	The role of staging laparoscopy in complex bariatric surgery. <i>Clinical Obesity</i> , 2021 , 11, e12460	3.6
359	Weight loss with bariatric surgery or behaviour modification and the impact on female obesity-related urine incontinence: A comprehensive systematic review and meta-analysis. <i>Clinical Obesity</i> , 2021 , 11, e12450	3.6 1
358	Obesity and responsibility: Is it time to rethink agency?. <i>Obesity Reviews</i> , 2021 , 22, e13270	10.6 6
357	An Exploration of the Patient Lived Experience of Remission and Relapse of Type 2 Diabetes Following Bariatric Surgery. <i>Obesity Surgery</i> , 2021 , 31, 3919-3925	3.7 0
356	Duodenal-jejunal Bypass Liner for the management of Type 2 Diabetes Mellitus and Obesity: A Multicenter Randomized Controlled Trial. <i>Annals of Surgery</i> , 2021 , 275,	7.8 6
355	Early experience with a nutrition and survivorship clinic in esophageal cancer. <i>Ecological Management and Restoration</i> , 2021 , 34,	3 2
354	Dipeptidyl peptidase-4 activity, lipopolysaccharide, C-reactive protein, glucose metabolism, and gut peptides 3 months after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2021 , 17, 113-120	3 1
353	Remission and progression of pre-existing micro- and macroalbuminuria over 15 years after bariatric surgery in Swedish Obese Subjects study. <i>International Journal of Obesity</i> , 2021 , 45, 535-546	5.5 6
352	Exploring patient beliefs and perceptions regarding obesity as a disease, obesity causation and treatment. <i>Irish Journal of Medical Science</i> , 2021 , 190, 163-168	1.9 4
351	The altered enteroendocrine repertoire following roux-en-Y-gastric bypass as an effector of weight loss and improved glycaemic control. <i>Appetite</i> , 2021 , 156, 104807	4.5 13
350	A Pilot Study of Gut-Brain Signaling After Octreotide Therapy for Unintentional Weight Loss After Esophagectomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e204-e216	5.6 1
349	COVID-19 alters thinking and management in metabolic diseases. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 71-72	15.2 13
348	Bariatric Surgery: There Is a Room for Improvement to Reduce Mortality in Patients with Type 2 Diabetes. <i>Obesity Surgery</i> , 2021 , 31, 461-463	3.7 2

347	Metabolic surgery versus conventional therapy in type 2 diabetes. <i>Lancet, The</i> , 2021 , 397, 256-257	4.0	1
346	Other Potential Benefits of the Sleeve: Effects on Body Fat Setpoint 2021 , 393-401		
345	Effect of the Natural Sweetener Xylitol on Gut Hormone Secretion and Gastric Emptying in Humans: A Pilot Dose-Ranging Study. <i>Nutrients</i> , 2021 , 13,	6.7	3
344	Management of Obesity in Adults with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021 ,	12.7	8
343	Methodological issues in assessing change in dietary intake and appetite following gastric bypass surgery: A systematic review. <i>Obesity Reviews</i> , 2021 , 22, e13202	10.6	5
342	Gastric emptying of solutions containing the natural sweetener erythritol and effects on gut hormone secretion in humans: A pilot dose-ranging study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1311-1321	6.7	3
341	Liraglutide Does Not Adversely Impact Fat-Free Mass Loss. <i>Obesity</i> , 2021 , 29, 529-534	8	0
340	Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?. <i>Nutrients</i> , 2021 , 13,	6.7	7
339	Endoscopic Evaluation and Management of Late Complications After Bariatric Surgery: a Narrative Review. <i>Obesity Surgery</i> , 2021 , 31, 4624-4633	3.7	4
338	Potential gut-brain mechanisms behind adverse mental health outcomes of bariatric surgery. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 549-559	15.2	6
337	The lived experience of patients with obesity: A systematic review and qualitative synthesis. <i>Obesity Reviews</i> , 2021 , 22, e13334	10.6	0
336	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2021 , e14669	3.5	2
335	Erythritol and xylitol differentially impact brain networks involved in appetite regulation in healthy volunteers. <i>Nutritional Neuroscience</i> , 2021 , 1-15	3.6	1
334	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021 ,	14.6	15
333	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	4
332	Mechanisms of weight loss after obesity surgery. <i>Endocrine Reviews</i> , 2021 ,	27.2	5
331	Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial. <i>Diabetes Care</i> , 2021 ,	14.6	0
330	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021 , 64, 2359-2366	10.3	7

329	"You Are Always at War With Yourself" The Perceptions and Beliefs of People With Obesity Regarding Obesity as a Disease. <i>Qualitative Health Research</i> , 2021 , 31, 2470-2485	3.9	0
328	Glycemic Control and Metabolic Adaptation in Response to High-Fat versus High-Carbohydrate Diets-Data from a Randomized Cross-Over Study in Healthy Subjects. <i>Nutrients</i> , 2021 , 13,	6.7	1
327	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. <i>Lancet, The</i> , 2021 ,	4.0	22
326	Glycemic Control and Reduction of Cardiorenal Risk Following Bariatric Surgery 2021 , 1-9		
325	Amylin as a Future Obesity Treatment.. <i>Journal of Obesity and Metabolic Syndrome</i> , 2021 , 30, 320-325	4.4	2
324	Simulating the Post-gastric Bypass Intestinal Microenvironment Uncovers a Barrier-Stabilizing Role for FXR. <i>IScience</i> , 2020 , 23, 101777	6.1	3
323	Can Metabolic Surgery Be Used to Improve Access to and Outcomes of Kidney Transplantation?. <i>Obesity</i> , 2020 , 28, 2259	8	
322	Suppression of enteroendocrine cell glucagon-like peptide (GLP)-1 release by fat-induced small intestinal ketogenesis: a mechanism targeted by Roux-en-Y gastric bypass surgery but not by preoperative very-low-calorie diet. <i>Gut</i> , 2020 , 69, 1423-1431	19.2	7
321	Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. <i>Lancet Diabetes and Endocrinology,the</i> , 2020 , 8, 640-648	18.1	94
320	Obesity, cardiovascular risk and healthcare resource utilization in the UK. <i>European Journal of Preventive Cardiology</i> , 2020 , 2047487320925639	3.9	6
319	Metabolic dysfunction and diabetes mellitus during long-term follow-up of severe acute pancreatitis: A case-matched study. <i>Pancreatology</i> , 2020 , 20, 813-821	3.8	2
318	Gastric bypass in female rats lowers concentrated sugar solution intake and preference without affecting brief-access licking after long-term sugar exposure. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2020 , 318, R870-R885	3.2	6
317	Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery. <i>Frontiers in Endocrinology</i> , 2020 , 11, 408	5.7	7
316	Improving understanding of type 2 diabetes remission: research recommendations from Diabetes UKQ 2019 remission workshop. <i>Diabetic Medicine</i> , 2020 , 37, 1944-1950	3.5	2
315	Oxyntomodulin and Glicentin May Predict the Effect of Bariatric Surgery on Food Preferences and Weight Loss. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	24
314	Patient perceptions and understanding of obesity related endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2020 , 32, 100545	1.3	4
313	Joint international consensus statement for ending stigma of obesity. <i>Nature Medicine</i> , 2020 , 26, 485-497	30.5	210
312	The Effect of Metabolic Surgery on the Complications of Diabetes: What Are the Unanswered Questions?. <i>Frontiers in Endocrinology</i> , 2020 , 11, 304	5.7	6

311	Predictors of weight loss after bariatric surgery-a cross-disciplinary approach combining physiological, social, and psychological measures. <i>International Journal of Obesity</i> , 2020 , 44, 2291-2302	5.5	11
310	Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial. <i>BMJ Open</i> , 2020 , 10, e034137	3	1
309	The metabolic benefits of different bariatric operations: what procedure to choose?. <i>Endocrine Connections</i> , 2020 , 9, R28-R35	3.5	17
308	Gastric Bypass: Mechanisms of Functioning 2020 , 7-21		1
307	Can Bariatric Surgery Improve the Microvascular Complications of Type 2 Diabetes? 2020 , 469-477		
306	Evaluation of Heart Rate Variability and Endothelial Function 3Months After Bariatric Surgery. <i>Obesity Surgery</i> , 2020 , 30, 2450-2453	3.7	2
305	Improvements in diabetic albuminuria and podocyte differentiation following Roux-en-Y gastric bypass surgery. <i>Diabetes and Vascular Disease Research</i> , 2020 , 17, 1479164119879039	3.3	13
304	Comment on: Impact of serum uric acid on renal function after bariatric surgery: a retrospective study. <i>Surgery for Obesity and Related Diseases</i> , 2020 , 16, 295-298	3	1
303	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. <i>Diabetologia</i> , 2020 , 63, 473-485	10.3	11
302	Continuous Glucose Monitoring of Glycemic Variability During Fasting Post-Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2020 , 30, 3721-3729	3.7	
301	Double-blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study. <i>Obesity Science and Practice</i> , 2020 , 6, 255-263	2.6	7
300	Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus. <i>Nature Reviews Nephrology</i> , 2020 , 16, 709-720	14.9	28
299	Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a cross-sectional study in a tertiary nephrology centre. <i>Clinical Obesity</i> , 2020 , 10, e12402	3.6	10
298	Comparison of Preoperative Remission Scores and Diabetes Duration Alone as Predictors of Durable Type 2 Diabetes Remission and Risk of Diabetes Complications After Bariatric Surgery: A Post Hoc Analysis of Participants From the Swedish Obese Subjects Study. <i>Diabetes Care</i> , 2020 , 43, 2804-2811	14.6	9
297	"I am terrified of something happening to me" The lived experience of people with obesity during the COVID-19 pandemic. <i>Clinical Obesity</i> , 2020 , 10, e12406	3.6	12
296	Parallel assessment of albuminuria and plasma sTNFR1 in people with type 2 diabetes and advanced chronic kidney disease provides accurate prognostication of the risks of renal decline and death. <i>Scientific Reports</i> , 2020 , 10, 14852	4.9	3
295	Effects of acute aerobic, resistance and combined exercises on 24-h glucose variability and skeletal muscle signalling responses in type 1 diabetics. <i>European Journal of Applied Physiology</i> , 2020 , 120, 2677-2691	3.4	4
294	Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?. <i>Frontiers in Endocrinology</i> , 2020 , 11, 289	5.7	20

293	Characterization of the renal cortical transcriptome following Roux-en-Y gastric bypass surgery in experimental diabetic kidney disease. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	6
292	Long-term outcomes of bariatric surgery in patients with diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2020 , 15, 141-146	4.1	5
291	Bariatric Surgery Leads to Short-Term Effects on Sweet Taste Sensitivity and Hedonic Evaluation of Fatty Food Stimuli. <i>Obesity</i> , 2019 , 27, 1796-1804	8	18
290	Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery. <i>Obesity Surgery</i> , 2019 , 29, 4095-4104	3.7	8
289	Risk factors for loss of bone mineral density after curative esophagectomy. <i>Archives of Osteoporosis</i> , 2019 , 14, 6	2.9	4
288	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. <i>Metabolism: Clinical and Experimental</i> , 2019 , 100, 153960	12.7	12
287	Comment on: Metabolic surgery improves renal injury independent of weight loss: a meta-analysis. <i>Surgery for Obesity and Related Diseases</i> , 2019 , 15, 1020-1023	3	7
286	Fat free mass is positively associated with hunger and energy intake at extremes of obesity. <i>Appetite</i> , 2019 , 143, 104444	4.5	10
285	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 834-844	18.1	81
284	Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019 , 10, 2042018819875407	4.5	14
283	Impact of intentional weight loss on diabetic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2338-2341	6.7	7
282	Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Food Preferences and Potential Mechanisms Involved. <i>Current Obesity Reports</i> , 2019 , 8, 292-300	8.4	12
281	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study. <i>Diabetes Care</i> , 2019 , 42, 1446-1453	14.6	47
280	The influence of skeletal muscle on appetite regulation. <i>Expert Review of Endocrinology and Metabolism</i> , 2019 , 14, 267-282	4.1	17
279	Changes in gut hormones, glycaemic response and symptoms after oesophagectomy. <i>British Journal of Surgery</i> , 2019 , 106, 735-746	5.3	9
278	Attenuation of satiety gut hormones increases appetitive behavior after curative esophagectomy for esophageal cancer. <i>American Journal of Clinical Nutrition</i> , 2019 , 109, 335-344	7	5
277	Simulation of gastric bypass effects on glucose metabolism and non-alcoholic fatty liver disease with the Sleeveballoon device. <i>EBioMedicine</i> , 2019 , 46, 452-462	8.8	8
276	The Association Between Kidney Disease and Diabetes Remission in Bariatric Surgery Patients With Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 761-770	7.4	14

275	The Role of the Small Bowel in Unintentional Weight Loss after Treatment of Upper Gastrointestinal Cancers. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	1
274	Effect of Macronutrient Type and Gastrointestinal Release Site on PYY Response in Normal Healthy Subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3661-3669	5.6	1
273	Iron and Vitamin D/Calcium Deficiency after Gastric Bypass: Mechanisms Involved and Strategies to Improve Oral Supplement Disposition. <i>Current Drug Metabolism</i> , 2019 , 20, 244-252	3.5	11
272	Treating prediabetes: why and how should we do it?. <i>Minerva Medica</i> , 2019 , 110, 52-61	2.2	14
271	Vertical sleeve gastrectomy in adolescents reduces the appetitive reward value of a sweet and fatty reinforcer in a progressive ratio task. <i>Surgery for Obesity and Related Diseases</i> , 2019 , 15, 194-199	3	6
270	Photo-Assisted Dietary Method Improves Estimates of Dietary Intake Among People with Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2019 , 29, 1602-1606	3.7	3
269	Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1498-1501	6.7	35
268	Changes in glycaemic control, blood pressure and lipids 5 years following laparoscopic adjustable gastric banding combined with medical care in patients with type 2 diabetes: a longitudinal analysis. <i>Clinical Obesity</i> , 2018 , 8, 151-158	3.6	16
267	Incidence of end-stage renal disease following bariatric surgery in the Swedish Obese Subjects Study. <i>International Journal of Obesity</i> , 2018 , 42, 964-973	5.5	48
266	Optimisation of follow-up after metabolic surgery. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 487-491	4.1	29
265	Effect of Bariatric Surgery on CKD Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2018 , 29, 1289-1300	12.7	70
264	Glycemic Control after Sleeve Gastrectomy and Roux-En-Y Gastric Bypass in Obese Subjects with Type 2 Diabetes Mellitus. <i>Obesity Surgery</i> , 2018 , 28, 1461-1472	3.7	24
263	Integrated insights into the role of alpha-melanocyte stimulatory hormone in the control of food intake and glycaemia. <i>Peptides</i> , 2018 , 100, 243-248	3.8	1
262	Patient profiling for success after weight loss surgery (GO Bypass study): An interdisciplinary study protocol. <i>Contemporary Clinical Trials Communications</i> , 2018 , 10, 121-130	1.8	14
261	Surgery: The new gold-standard - medical gastric bypass. <i>Nature Reviews Endocrinology</i> , 2018 , 14, 257-258	5.2	6
260	EndoBarrier [®] : a Safe and Effective Novel Treatment for Obesity and Type 2 Diabetes?. <i>Obesity Surgery</i> , 2018 , 28, 1980-1989	3.7	22
259	Preoperative weight loss with glucagon-like peptide-1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 745-748	6.7	7
258	Validating the association between plasma tumour necrosis factor receptor 1 levels and the presence of renal injury and functional decline in patients with Type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 95-99	3.2	8

257	Impact of Abdominal Subcutaneous Fat Reduction on Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus. <i>Bariatric Surgical Patient Care</i> , 2018 , 13, 25-32	0.4	1
256	Obesity and healthcare resource utilization: results from Clinical Practice Research Database (CPRD). <i>Obesity Science and Practice</i> , 2018 , 4, 409-416	2.6	8
255	Food Intake and Eating Behavior After Bariatric Surgery. <i>Physiological Reviews</i> , 2018 , 98, 1113-1141	47.9	72
254	Reply: Bariatric surgery and chronic kidney disease: much hope, but proof is still awaited. <i>International Journal of Obesity</i> , 2018 , 42, 1534	5.5	
253	Bariatric Surgery for Obesity. <i>Medical Clinics of North America</i> , 2018 , 102, 165-182	7	55
252	Sugar Detection Threshold After Laparoscopic Sleeve Gastrectomy in Adolescents. <i>Obesity Surgery</i> , 2018 , 28, 1302-1307	3.7	6
251	Metabolic Effects of Bariatric Surgery. <i>Clinical Chemistry</i> , 2018 , 64, 72-81	5.5	16
250	Detailed Description of Change in Serum Cholesterol Profile with Incremental Weight Loss After Restrictive Bariatric Surgery. <i>Obesity Surgery</i> , 2018 , 28, 1351-1362	3.7	5
249	Measurement of glomerular filtration rate in patients undergoing obesity surgery. <i>BMC Nephrology</i> , 2018 , 19, 383	2.7	6
248	Bariatric Surgery Does Not Affect Food Preferences, but Individual Changes in Food Preferences May Predict Weight Loss. <i>Obesity</i> , 2018 , 26, 1879-1887	8	40
247	Impact of bariatric surgery on cardiovascular and renal complications of diabetes: a focus on clinical outcomes and putative mechanisms. <i>Expert Review of Endocrinology and Metabolism</i> , 2018 , 13, 251-262	4.1	25
246	Current and emerging pharmacotherapy for prediabetes: are we moving forward?. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1663-1673	4	5
245	Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 606-624	24.2	43
244	Obesity surgery makes patients healthier and more functional: real world results from the United Kingdom National Bariatric Surgery Registry. <i>Surgery for Obesity and Related Diseases</i> , 2018 , 14, 1033-1040	24	28
243	How Ethical Is Our Current Delivery of Care to Patients with Severe and Complicated Obesity?. <i>Obesity Surgery</i> , 2018 , 28, 2078-2082	3.7	8
242	Biliopancreatic Diversion is associated with greater increases in energy expenditure than Roux-en-Y Gastric Bypass. <i>PLoS ONE</i> , 2018 , 13, e0194538	3.7	9
241	Differential response of plasma plasminogen activator inhibitor 1 after weight loss surgery in patients with or without type 2 diabetes. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 53-57	3	7
240	Unmet need for bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 1052-1056	3	10

239	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. <i>Lancet, The</i> , 2017 , 389, 1399-1409	4.0	324
238	Microvascular Outcomes after Metabolic Surgery (MOMS) in patients with type 2 diabetes mellitus and class I obesity: rationale and design for a randomised controlled trial. <i>BMJ Open</i> , 2017 , 7, e013574	3	15
237	Weight loss after laparoscopic adjustable gastric band and resolution of the metabolic syndrome and its components. <i>International Journal of Obesity</i> , 2017 , 41, 902-908	5.5	9
236	Outcomes of Diabetic Microvascular Complications After Bariatric Surgery 2017 , 137-144		
235	Roux-En-Y Gastric Bypass and Sleeve Gastrectomy Does Not Affect Food Preferences When Assessed by an Ad libitum Buffet Meal. <i>Obesity Surgery</i> , 2017 , 27, 2599-2605	3.7	42
234	Metabolic Surgery in a Pill. <i>Cell Metabolism</i> , 2017 , 25, 985-987	24.6	7
233	Diabetes-associated microbiota in fa/fa rats is modified by Roux-en-Y gastric bypass. <i>ISME Journal</i> , 2017 , 11, 2035-2046	11.9	37
232	Urinary sodium excretion after gastric bypass surgery. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 1506-1514	3	15
231	Weight Loss, Satiety, and the Postprandial Gut Hormone Response After Esophagectomy: A Prospective Study. <i>Annals of Surgery</i> , 2017 , 266, 82-90	7.8	32
230	Bile acid profiles over 5 years after gastric bypass and duodenal switch: results from a randomized clinical trial. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 1544-1553	3	38
229	What is the impact on the healthcare system if access to bariatric surgery is delayed?. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 1619-1627	3	21
228	Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection. <i>Physiology and Behavior</i> , 2017 , 177, 4-12	3.5	6
227	Elevated fasting and postprandial C-terminal telopeptide after Roux-en-Y gastric bypass. <i>Annals of Clinical Biochemistry</i> , 2017 , 54, 495-500	2.2	3
226	Dumping symptoms is triggered by fat as well as carbohydrates in patients operated with Roux-en-Y gastric bypass. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 1159-1164	3	9
225	Letter to the Editor Regarding Equivalent Increases in Circulating GLP-1 Following Jejunal Delivery of Intact and Hydrolysed Casein: Relevance to Satiety Induction following Bariatric Surgery. <i>Obesity Surgery</i> , 2017 , 27, 816-817	3.7	1
224	Gastrointestinal surgery for obesity and cancer: 2 sides of the same coin. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 720-721	3	12
223	Validated Scoring Systems for Predicting Diabetes Remission After Bariatric Surgery. <i>Bariatric Surgical Patient Care</i> , 2017 , 12, 153-161	0.4	1
222	Morbidity and mortality associated with obesity. <i>Annals of Translational Medicine</i> , 2017 , 5, 161	3.2	341

221	The role of bariatric surgery to treat diabetes: current challenges and perspectives. <i>BMC Endocrine Disorders</i> , 2017 , 17, 50	3.3	72
220	Measurement of hepatic insulin sensitivity early after the bypass of the proximal small bowel in humans. <i>Obesity Science and Practice</i> , 2017 , 3, 95-98	2.6	4
219	Roux-En-Y Gastric Bypass in Type 2 Diabetes Patients with Mild Obesity: a Systematic Review and Meta-analysis. <i>Obesity Surgery</i> , 2017 , 27, 2733-2739	3.7	21
218	Do Food Preferences Change After Bariatric Surgery?. <i>Current Atherosclerosis Reports</i> , 2017 , 19, 38	6	30
217	Aetiology of obesity in adults 2017 , 85-137		
216	Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m ² A Post-hoc Analysis. <i>Obesity Facts</i> , 2017 , 10, 531-544	5.1	19
215	Shifts in Food Preferences After Bariatric Surgery: Observational Reports and Proposed Mechanisms. <i>Current Obesity Reports</i> , 2017 , 6, 246-252	8.4	20
214	Effect of Roux-en-Y gastric bypass and diet-induced weight loss on diabetic kidney disease in the Zucker diabetic fatty rat. <i>Surgery for Obesity and Related Diseases</i> , 2017 , 13, 21-27	3	24
213	Renal Function and Remission of Hypertension After Bariatric Surgery: a 5-Year Prospective Cohort Study. <i>Obesity Surgery</i> , 2017 , 27, 613-619	3.7	32
212	A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus. <i>BMJ Open</i> , 2017 , 7, e018598	3	9
211	Changes in Bile Acid Profile After Laparoscopic Sleeve Gastrectomy are Associated with Improvements in Metabolic Profile and Fatty Liver Disease. <i>Obesity Surgery</i> , 2016 , 26, 1195-202	3.7	57
210	Future Prospects of the Management of Appetite Disorders 2016 , 224-246		1
209	Differential effects of L-tryptophan and L-leucine administration on brain resting state functional networks and plasma hormone levels. <i>Scientific Reports</i> , 2016 , 6, 35727	4.9	4
208	Physiology, pathophysiology and therapeutic implications of enteroendocrine control of food intake. <i>Expert Review of Endocrinology and Metabolism</i> , 2016 , 11, 475-499	4.1	13
207	Mechanisms underpinning remission of albuminuria following bariatric surgery. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016 , 23, 366-72	4	6
206	Changes in one-carbon metabolism after duodenal-jejunal bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016 , 310, E624-E632	6	5
205	The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 49	6	15
204	Capsaicin-induced satiety is associated with gastrointestinal distress but not with the release of satiety hormones. <i>American Journal of Clinical Nutrition</i> , 2016 , 103, 305-13	7	32

203	Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review. <i>Obesity Surgery</i> , 2016 , 26, 410-21	3.7	98
202	Food Intake and Changes in Eating Behavior After Laparoscopic Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2016 , 26, 2059-2067	3.7	56
201	Bariatric surgery: traversing the CROSSROADS into mainstream diabetes care. <i>Diabetologia</i> , 2016 , 59, 942-4	10.3	1
200	Improved glucose metabolism after gastric bypass: evolution of the paradigm. <i>Surgery for Obesity and Related Diseases</i> , 2016 , 12, 1457-1465	3	26
199	Link Between Increased Satiety Gut Hormones and Reduced Food Reward After Gastric Bypass Surgery for Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 599-609	5.6	77
198	NICE-Accredited Commissioning Guidance for Weight Assessment and Management Clinics: a Model for a Specialist Multidisciplinary Team Approach for People with Severe Obesity. <i>Obesity Surgery</i> , 2016 , 26, 649-59	3.7	29
197	Equivalent Increases in Circulating GLP-1 Following Jejunal Delivery of Intact and Hydrolysed Casein: Relevance to Satiety Induction Following Bariatric Surgery. <i>Obesity Surgery</i> , 2016 , 26, 1851-8	3.7	5
196	Impact of Duodenal-Jejunal Exclusion on Satiety Hormones. <i>Obesity Surgery</i> , 2016 , 26, 672-8	3.7	23
195	The Neurobiological Impact of Ghrelin Suppression after Oesophagectomy. <i>International Journal of Molecular Sciences</i> , 2016 , 18,	6.3	1
194	Glycaemic Control and Reduction of Cardiovascular Risk Following Bariatric Surgery 2016 , 529-534		
193	Mechanisms of Action of Bariatric Surgical Procedures 2016 , 519-527		
192	How do patients' clinical phenotype and the physiological mechanisms of the operations impact the choice of bariatric procedure?. <i>Clinical and Experimental Gastroenterology</i> , 2016 , 9, 181-9	3.1	3
191	The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?. <i>Diabetes and Metabolism Journal</i> , 2016 , 40, 354-364	5	24
190	Reconfiguration of the small intestine and diabetes remitting effects of Roux-en-Y gastric bypass surgery. <i>Current Opinion in Gastroenterology</i> , 2016 , 32, 61-6	3	6
189	Why the NHS should do more bariatric surgery; how much should we do?. <i>BMJ, The</i> , 2016 , 353, i1472	5.9	46
188	Roux-en-Y gastric bypass in rats progressively decreases the proportion of fat calories selected from a palatable cafeteria diet. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016 , 310, R952-9	3.2	35
187	The Diabetes Surgery Summit II Guidelines: a Disease-Based Clinical Recommendation. <i>Obesity Surgery</i> , 2016 , 26, 1989-91	3.7	14
186	A novel technique of Roux-en-Y gastric bypass reversal for postprandial hyperinsulinemic hypoglycaemia: A case report. <i>International Journal of Surgery Case Reports</i> , 2016 , 21, 91-4	0.8	12

185	Remission of type 2 diabetes in patients undergoing biliointestinal bypass for morbid obesity: a new surgical treatment. <i>Surgery for Obesity and Related Diseases</i> , 2016 , 12, 815-821	3	8
184	Hedonic Changes in Food Choices Following Roux-en-Y Gastric Bypass. <i>Obesity Surgery</i> , 2016 , 26, 1946-55,7	5.7	21
183	Differences in Regional Brain Responses to Food Ingestion After Roux-en-Y Gastric Bypass and the Role of Gut Peptides: A Neuroimaging Study. <i>Diabetes Care</i> , 2016 , 39, 1787-95	14.6	15
182	Exposure-response analyses of liraglutide 3.0 mg for weight management. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 491-9	6.7	40
181	Which Organ is Responsible for the Pathogenesis of Obesity?. <i>Irish Medical Journal</i> , 2016 , 109, 395	0.7	0
180	Changes in Glucose Metabolism in Vertical Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2015 , 25, 2002-10	3.7	7
179	Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. <i>Cell Metabolism</i> , 2015 , 22, 228-38	24.6	489
178	Effects of high-fat diet and gastric bypass on neurons in the caudal solitary nucleus. <i>Physiology and Behavior</i> , 2015 , 152, 329-39	3.5	6
177	Maternal C-reactive protein in early pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2015 , 193, 79-82	2.4	7
176	Weight loss interventions and progression of diabetic kidney disease. <i>Current Diabetes Reports</i> , 2015 , 15, 55	5.6	13
175	A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. <i>New England Journal of Medicine</i> , 2015 , 373, 11-22	59.2	950
174	Circulating pancreatic polypeptide concentrations predict visceral and liver fat content. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1048-52	5.6	13
173	Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case-control study. <i>Diabetologia</i> , 2015 , 58, 1443-7	10.3	62
172	Cardiovascular, renal and overall health outcomes after bariatric surgery. <i>Current Cardiology Reports</i> , 2015 , 17, 34	4.2	7
171	Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. <i>JAMA Surgery</i> , 2015 , 150, 352-61	5.4	143
170	Treatment of obesity: bariatric surgery 2015 , 505-518		1
169	Changes in Reward after Gastric Bypass: the Advantages and Disadvantages. <i>Current Atherosclerosis Reports</i> , 2015 , 17, 61	6	12
168	Metabolic phenotype-microRNA data fusion analysis of the systemic consequences of Roux-en-Y gastric bypass surgery. <i>International Journal of Obesity</i> , 2015 , 39, 1126-34	5.5	25

167	Type 2 diabetes: multimodal treatment of a complex disease. <i>Lancet, The</i> , 2015 , 386, 936-7	4.0	15
166	Copper, selenium and zinc levels after bariatric surgery in patients recommended to take multivitamin-mineral supplementation. <i>Journal of Trace Elements in Medicine and Biology</i> , 2015 , 31, 167-72	4.1	45
165	Predicting refeeding hypophosphataemia: insulin growth factor 1 (IGF-1) as a diagnostic biochemical marker for clinical practice. <i>Annals of Clinical Biochemistry</i> , 2015 , 52, 82-7	2.2	20
164	Gut Hormone Suppression Increases Food Intake After Esophagectomy With Gastric Conduit Reconstruction. <i>Annals of Surgery</i> , 2015 , 262, 824-29; discussion 829-30	7.8	19
163	Roux-en-Y Gastric Bypass Surgery Increases Respiratory Quotient and Energy Expenditure during Food Intake. <i>PLoS ONE</i> , 2015 , 10, e0129784	3.7	26
162	Temporal changes in bile acid levels and 12 β hydroxylation after Roux-en-Y gastric bypass surgery in type 2 diabetes. <i>International Journal of Obesity</i> , 2015 , 39, 806-13	5.5	66
161	Psychological characteristics, eating behavior, and quality of life assessment of obese patients undergoing weight loss interventions. <i>Scandinavian Journal of Surgery</i> , 2015 , 104, 10-7	3.1	23
160	Anti-inflammatory effects of gastric bypass surgery and their association with improvement in metabolic profile. <i>Expert Review of Endocrinology and Metabolism</i> , 2015 , 10, 435-446	4.1	2
159	Physiological adaptations following Roux-en-Y gastric bypass and the identification of targets for bariatric mimetic pharmacotherapy. <i>Current Opinion in Pharmacology</i> , 2015 , 25, 23-9	5.1	6
158	Reduced sweet and fatty fluid intake after Roux-en-Y gastric bypass in rats is dependent on experience without change in stimulus motivational potency. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015 , 309, R864-74	3.2	34
157	Effect of bariatric surgery combined with medical therapy versus intensive medical therapy or calorie restriction and weight loss on glycemic control in Zucker diabetic fatty rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015 , 308, R321-9	3.2	12
156	Gastric bypass in rats does not decrease appetitive behavior towards sweet or fatty fluids despite blunting preferential intake of sugar and fat. <i>Physiology and Behavior</i> , 2015 , 142, 179-88	3.5	40
155	Impact of perioperative management of glycemia in severely obese diabetic patients undergoing gastric bypass surgery. <i>Surgery for Obesity and Related Diseases</i> , 2015 , 11, 578-84	3	11
154	Aspartame sensitivity? A double blind randomised crossover study. <i>PLoS ONE</i> , 2015 , 10, e0116212	3.7	7
153	Roux-en-Y Gastric Bypass Surgery Induces Early Plasma Metabolomic and Lipidomic Alterations in Humans Associated with Diabetes Remission. <i>PLoS ONE</i> , 2015 , 10, e0126401	3.7	43
152	Truncating Homozygous Mutation of Carboxypeptidase E (CPE) in a Morbidly Obese Female with Type 2 Diabetes Mellitus, Intellectual Disability and Hypogonadotropic Hypogonadism. <i>PLoS ONE</i> , 2015 , 10, e0131417	3.7	46
151	Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion. <i>Diabetes</i> , 2014 , 63, 1069-78	0.9	42
150	The effect of bariatric surgery on intestinal absorption and transit time. <i>Obesity Surgery</i> , 2014 , 24, 796-805	3.7	81

149	Bariatric surgery: the indications in metabolic disease. <i>Digestive Surgery</i> , 2014 , 31, 6-12	2.5	10
148	The gut-brain axis in obesity. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2014 , 28, 559-71	2.5	45
147	Roux-en Y gastric bypass is superior to duodeno-jejunal bypass in improving glycaemic control in Zucker diabetic fatty rats. <i>Obesity Surgery</i> , 2014 , 24, 1888-95	3.7	18
146	Intestinal sweet-sensing pathways and metabolic changes after Roux-en-Y gastric bypass surgery. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 307, G588-93	5.1	21
145	More symptoms but similar blood glucose curve after oral carbohydrate provocation in patients with a history of hypoglycemia-like symptoms compared to asymptomatic patients after Roux-en-Y gastric bypass. <i>Surgery for Obesity and Related Diseases</i> , 2014 , 10, 1047-54	3	24
144	Preoperative assessment of gut hormones does not correlate to weight loss after Roux-en-Y gastric bypass surgery. <i>Surgery for Obesity and Related Diseases</i> , 2014 , 10, 822-8	3	7
143	Body mass index and diabetes status do not affect postoperative infection rates after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2014 , 10, 291-7	3	13
142	Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 141-51	18.1	28
141	Improving patient waiting times: a simulation study of an obesity care service. <i>BMJ Quality and Safety</i> , 2014 , 23, 373-81	5.4	13
140	Endogenous Glucagon-Like Peptide-1 as a Potential Mediator of the Resolution of Diabetic Kidney Disease Following Roux en Y Gastric Bypass: Evidence and Perspectives. <i>Advances in Endocrinology</i> , 2014 , 2014, 1-11		1
139	Can medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?. <i>International Journal of Obesity</i> , 2014 , 38, 325-33	5.5	47
138	The role of bariatric surgery in the treatment of diabetes. <i>Therapeutic Advances in Chronic Disease</i> , 2014 , 5, 149-57	4.9	12
137	Bone mineral density and expression of vitamin D receptor-dependent calcium uptake mechanisms in the proximal small intestine after bariatric surgery. <i>British Journal of Surgery</i> , 2014 , 101, 1566-75	5.3	19
136	Improvements in the metabolic milieu following Roux-en-Y gastric bypass and the arrest of diabetic kidney disease. <i>Experimental Physiology</i> , 2014 , 99, 1146-53	2.4	20
135	Application of the International Diabetes Federation and American Diabetes Association criteria in the assessment of metabolic control after bariatric surgery. <i>Diabetes, Obesity and Metabolism</i> , 2014 , 16, 86-9	6.7	20
134	The physiology of altered eating behaviour after Roux-en-Y gastric bypass. <i>Experimental Physiology</i> , 2014 , 99, 1128-32	2.4	37
133	Physiological and pathophysiological signalling between the gut and the kidney: role in diabetic kidney disease. <i>Experimental Physiology</i> , 2014 , 99, 1138-9	2.4	2
132	Bariatric surgery and microvascular complications of type 2 diabetes mellitus. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 453	6	22

131	Obese patients after gastric bypass surgery have lower brain-hedonic responses to food than after gastric banding. <i>Gut</i> , 2014 , 63, 891-902	19.2	198
130	Rats fed diets with different energy contribution from fat do not differ in adiposity. <i>Obesity Facts</i> , 2014 , 7, 302-10	5.1	6
129	Where to begin and where to end? Preoperative assessment for patients undergoing metabolic surgery. <i>Digestive Surgery</i> , 2014 , 31, 25-32	2.5	5
128	Can we predict diabetes remission after weight-loss surgery?. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 4-6	18.1	3
127	Beyond weight loss: evaluating the multiple benefits of bariatric surgery after Roux-en-Y gastric bypass and adjustable gastric band. <i>Obesity Surgery</i> , 2014 , 24, 684-91	3.7	21
126	Urine bile acids relate to glucose control in patients with type 2 diabetes mellitus and a body mass index below 30 kg/m ² . <i>PLoS ONE</i> , 2014 , 9, e93540	3.7	19
125	The Controversies Around Roux-en-Y Gastric Bypass 2014 , 253-261		
124	Mechanisms of Bariatric Surgery 2014 , 137-148		
123	Metabolic Effects of Bariatric Surgery: A Focus on Inflammation and Diabetic Kidney Disease. <i>Current Obesity Reports</i> , 2013 , 2, 120-127	8.4	1
122	Mechanisms underlying weight loss after bariatric surgery. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 575-84	24.2	200
121	Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes. <i>BMC Medicine</i> , 2013 , 11, 8	11.4	87
120	Effects of preoperative exposure to a high-fat versus a low-fat diet on ingestive behavior after gastric bypass surgery in rats. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013 , 27, 4192-201	5.2	31
119	Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. <i>Obesity Surgery</i> , 2013 , 23, 1354-60	3.7	112
118	Changes in gut hormone profile and glucose homeostasis after laparoscopic sleeve gastrectomy. <i>Surgery for Obesity and Related Diseases</i> , 2013 , 9, 192-201	3	52
117	Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. <i>Scandinavian Journal of Gastroenterology</i> , 2013 , 48, 1257-64	2.4	66
116	Role of proximal gut exclusion from food on glucose homeostasis in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2013 , 30, 1482-6	3.5	35
115	Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. <i>Surgery for Obesity and Related Diseases</i> , 2013 , 9, 559-68	3	96
114	Adherence to the National Institute of Clinical Excellence guidance on parenteral nutrition screening is not enough to improve outcomes. <i>Clinical Nutrition</i> , 2013 , 32, 73-6	5.9	4

113	Fast-track laparoscopic bariatric surgery: a systematic review. <i>Updates in Surgery</i> , 2013 , 65, 85-94	2.9	53
112	Long-term results of a randomized clinical trial comparing Roux-en-Y gastric bypass with vertical banded gastroplasty. <i>British Journal of Surgery</i> , 2013 , 100, 222-30	5.3	34
111	Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine. <i>Physiology and Behavior</i> , 2013 , 119, 92-6	3.5	75
110	Urinary phenotyping indicates weight loss-independent metabolic effects of Roux-en-Y gastric bypass in mice. <i>Journal of Proteome Research</i> , 2013 , 12, 1245-53	5.6	16
109	Bariatric surgery: a best practice article. <i>Journal of Clinical Pathology</i> , 2013 , 66, 90-8	3.9	41
108	The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation. <i>Nephrology Dialysis Transplantation</i> , 2013 , 28 Suppl 4, iv73-82	4.3	29
107	Are bile acids the new gut hormones? Lessons from weight loss surgery models. <i>Endocrinology</i> , 2013 , 154, 2255-6	4.8	35
106	Higher circulating bile acid concentrations in obese patients with type 2 diabetes. <i>Annals of Clinical Biochemistry</i> , 2013 , 50, 360-4	2.2	52
105	Duodenal-jejunal bypass liners: outcomes in glycaemic control and weight loss. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2013 , 20, 420-8	4	3
104	Incretins: new targets for the prevention of diabetes and obesity. <i>Clinical Lipidology</i> , 2013 , 8, 109-121		1
103	Twenty-four hour energy expenditure and skeletal muscle gene expression changes after bariatric surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E321-7	5.6	19
102	Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. <i>Diabetic Medicine</i> , 2013 , 30, 1495-9	3.5	44
101	Gastric bypass surgery alters food preferences through changes in the perception of taste. <i>Clinical Practice (London, England)</i> , 2013 , 10, 471-479	3	4
100	Increased postprandial energy expenditure may explain superior long term weight loss after Roux-en-Y gastric bypass compared to vertical banded gastroplasty. <i>PLoS ONE</i> , 2013 , 8, e60280	3.7	72
99	Can a protocol for glycaemic control improve type 2 diabetes outcomes after gastric bypass?. <i>Obesity Surgery</i> , 2012 , 22, 90-6	3.7	24
98	Bariatric surgery for type 2 diabetes. <i>Lancet, The</i> , 2012 , 379, 2300-11	4.0	223
97	Mechanisms of weight loss, diabetes control and changes in food choices after gastrointestinal surgery. <i>Current Atherosclerosis Reports</i> , 2012 , 14, 616-23	6	17
96	Metabolic surgery and obstructive sleep apnoea: the protective effects of bariatric procedures. <i>Thorax</i> , 2012 , 67, 442-9	7.3	70

95	Cerebral markers of the serotonergic system in rat models of obesity and after Roux-en-Y gastric bypass. <i>Obesity</i> , 2012 , 20, 2133-41	8	22
94	Effect of bypassing the proximal gut on gut hormones involved with glycemic control and weight loss. <i>Surgery for Obesity and Related Diseases</i> , 2012 , 8, 371-4	3	48
93	Gut hormones and leptin: impact on energy control and changes after bariatric surgery--what the future holds. <i>Obesity Surgery</i> , 2012 , 22, 1648-57	3.7	37
92	Bariatric surgery: a European perspective. <i>European Diabetes Nursing</i> , 2012 , 9, 22-25		
91	Roux-en-Y gastric bypass in mice--surgical technique and characterisation. <i>Obesity Surgery</i> , 2012 , 22, 1117-25	3.7	18
90	Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. <i>British Journal of Pharmacology</i> , 2012 , 165, 414-23	8.6	151
89	High density lipoprotein in patients with liver failure; relation to sepsis, adrenal function and outcome of illness. <i>Liver International</i> , 2012 , 32, 128-36	7.9	33
88	Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. <i>British Journal of Surgery</i> , 2012 , 99, 100-3	5.3	145
87	Effect of vertical sleeve gastrectomy in melanocortin receptor 4-deficient rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012 , 303, E103-10	6	37
86	Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. <i>Diabetes Care</i> , 2012 , 35, e81	14.6	57
85	Improved blood pressure, nitric oxide and asymmetric dimethylarginine are independent after bariatric surgery. <i>Annals of Clinical Biochemistry</i> , 2012 , 49, 589-94	2.2	5
84	Roux-en-Y gastric bypass in rats increases sucrose taste-related motivated behavior independent of pharmacological GLP-1-receptor modulation. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2012 , 302, R751-67	3.2	53
83	GLP-1 and glucagon secretion from a pancreatic neuroendocrine tumor causing diabetes and hyperinsulinemic hypoglycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 3039-45	5.6	16
82	The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. <i>Endocrinology</i> , 2012 , 153, 3613-9	4.8	305
81	Gastric bypass surgery for obesity decreases the reward value of a sweet-fat stimulus as assessed in a progressive ratio task. <i>American Journal of Clinical Nutrition</i> , 2012 , 96, 467-73	7	122
80	Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas octreotide increases food intake in rats after Roux-en-Y gastric bypass. <i>International Journal of Obesity</i> , 2012 , 36, 379-84	5.5	40
79	Increased energy expenditure in gastric bypass rats is not caused by activated brown adipose tissue. <i>Obesity Facts</i> , 2012 , 5, 349-58	5.1	16
78	Roux-en-Y gastric bypass operation in rats. <i>Journal of Visualized Experiments</i> , 2012 , e3940	1.6	25

77	Gastrointestinal Physiology in Obesity 2012 , 21-27		
76	Gastrointestinal hormones, energy balance and bariatric surgery. <i>International Journal of Obesity</i> , 2011 , 35 Suppl 3, S35-9	5.5	36
75	Experimental bariatric surgery in rats generates a cytotoxic chemical environment in the gut contents. <i>Frontiers in Microbiology</i> , 2011 , 2, 183	5.7	56
74	The relationship between postprandial bile acid concentration, GLP-1, PYY and ghrelin. <i>Clinical Endocrinology</i> , 2011 , 74, 67-72	3.4	49
73	Alterations of sucrose preference after Roux-en-Y gastric bypass. <i>Physiology and Behavior</i> , 2011 , 104, 709-21	3.5	142
72	Pancreatic polypeptide meal response may predict gastric band-induced weight loss. <i>Obesity Surgery</i> , 2011 , 21, 1906-13	3.7	11
71	Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. <i>Journal of Parenteral and Enteral Nutrition</i> , 2011 , 35, 169-80	4.2	59
70	Metabolic surgery profoundly influences gut microbial-host metabolic cross-talk. <i>Gut</i> , 2011 , 60, 1214-23	19.2	319
69	Sodium and water handling after gastric bypass surgery in a rat model. <i>Surgery for Obesity and Related Diseases</i> , 2011 , 7, 68-73	3	23
68	Heart remodelling and obesity: the complexities and variation of cardiac geometry. <i>Heart</i> , 2011 , 97, 171-3	3.1	34
67	Lessons learned from gastric bypass operations in rats. <i>Obesity Facts</i> , 2011 , 4 Suppl 1, 3-12	5.1	35
66	Leptin and insulin growth factor 1: diagnostic markers of the refeeding syndrome and mortality. <i>British Journal of Nutrition</i> , 2011 , 106, 906-12	3.6	15
65	Gastric bypass reduces fat intake and preference. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2011 , 301, R1057-66	3.2	187
64	Leptin/adiponectin ratio in patients with coronary heart disease: comparing subjects with and without metabolic syndrome. <i>Annals of Clinical Biochemistry</i> , 2011 , 48, 327-31	2.2	12
63	The Role of Bile Acids in Gut-Hormone-Induced Weight Loss After Bariatric Surgery: Implications for Appetite Control and Diabetes 2011 , 1317-1330		2
62	Influence of adherence to the national guidance on nutrition screening and dietitian referral on clinical outcomes of those requiring parenteral nutrition. <i>Journal of Human Nutrition and Dietetics</i> , 2010 , 23, 190-3	3.1	3
61	Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. <i>Clinical Endocrinology</i> , 2010 , 72, 305-11	3.4	26
60	Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2010 , 72, 423-5	3.4	3

59	Ghrelin and metabolic surgery. <i>International Journal of Peptides</i> , 2010 , 2010,		28
58	Postprandial plasma bile acid responses in normal weight and obese subjects. <i>Annals of Clinical Biochemistry</i> , 2010 , 47, 482-4	2.2	70
57	Postprandial bone turnover is independent of calories above 250 kcal. <i>Annals of Clinical Biochemistry</i> , 2010 , 47, 318-20	2.2	11
56	Gastric bypass increases energy expenditure in rats. <i>Gastroenterology</i> , 2010 , 138, 1845-53	13.3	180
55	Eating slowly increases the postprandial response of the anorexigenic gut hormones, peptide YY and glucagon-like peptide-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 333-7	5.6	162
54	The role of bariatric surgery in the management of female fertility. <i>Human Fertility</i> , 2010 , 13, 67-71	1.9	9
53	Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. <i>Annals of Surgery</i> , 2010 , 252, 966-71	7.8	188
52	Bariatric surgery and taste: novel mechanisms of weight loss. <i>Current Opinion in Gastroenterology</i> , 2010 , 26, 140-5	3	114
51	Gut hypertrophy after gastric bypass is associated with increased glucagon-like peptide 2 and intestinal crypt cell proliferation. <i>Annals of Surgery</i> , 2010 , 252, 50-6	7.8	128
50	Upper gastrointestinal investigations before gastric banding. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2010 , 24, 1025-30	5.2	15
49	The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. <i>Obesity Surgery</i> , 2010 , 20, 56-60	3.7	70
48	Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass. <i>Obesity Surgery</i> , 2010 , 20, 616-22	3.7	69
47	Renal cytokines improve early after bariatric surgery. <i>British Journal of Surgery</i> , 2010 , 97, 1838-44	5.3	40
46	Mechanisms of weight loss after gastric bypass and gastric banding. <i>Obesity Facts</i> , 2009 , 2, 325-31	5.1	29
45	When the brakes came off: re-feeding oedema after deflation of a gastric band: a case report. <i>Obesity Surgery</i> , 2009 , 19, 1468-70	3.7	5
44	Obesity, gut hormones, and bariatric surgery. <i>World Journal of Surgery</i> , 2009 , 33, 1983-8	3.3	45
43	After bariatric surgery, what vitamins should be measured and what supplements should be given?. <i>Clinical Endocrinology</i> , 2009 , 71, 322-5	3.4	40
42	The mechanisms of weight loss after bariatric surgery. <i>International Journal of Obesity</i> , 2009 , 33 Suppl 1, S28-32	5.5	68

41	Metabolic surgery and gut hormones - a review of bariatric entero-humoral modulation. <i>Physiology and Behavior</i> , 2009 , 97, 620-31	3.5	75
40	A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. <i>Clinical Gastroenterology and Hepatology</i> , 2009 , 7, 1189-94	6.9	232
39	Serum total cortisol and free cortisol index give different information regarding the hypothalamus-pituitary-adrenal axis reserve in patients with liver impairment. <i>Annals of Clinical Biochemistry</i> , 2009 , 46, 505-7	2.2	27
38	Bariatric surgery and hypertension. <i>Surgery for Obesity and Related Diseases</i> , 2009 , 5, 615-20	3	24
37	Sir David Cuthbertson Medal Lecture. Bariatric surgery as a model to study appetite control. <i>Proceedings of the Nutrition Society</i> , 2009 , 68, 227-33	2.9	8
36	Changes in gut hormones after bariatric surgery. <i>Clinical Endocrinology</i> , 2008 , 69, 173-9	3.4	68
35	Mechanisms of disease: the role of gastrointestinal hormones in appetite and obesity. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 268-77		50
34	The effect of Khat (<i>Catha edulis</i>) as an appetite suppressant is independent of ghrelin and PYY secretion. <i>Appetite</i> , 2008 , 51, 747-50	4.5	31
33	The satiety hormone peptide YY as a regulator of appetite. <i>Journal of Clinical Pathology</i> , 2008 , 61, 548-53.9	3.9	37
32	Effects of bariatric surgery on cardiovascular function. <i>Circulation</i> , 2008 , 118, 2091-102	16.7	174
31	Supraphysiological doses of intravenous PYY3-36 cause nausea, but no additional reduction in food intake. <i>Annals of Clinical Biochemistry</i> , 2008 , 45, 93-5	2.2	50
30	Constitutional thinness and lean anorexia nervosa display opposite concentrations of peptide YY, glucagon-like peptide 1, ghrelin, and leptin. <i>American Journal of Clinical Nutrition</i> , 2007 , 85, 967-71	7	112
29	Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome. <i>American Journal of Clinical Nutrition</i> , 2007 , 86, 1603-10	7	63
28	Could a virus contribute to weight gain?. <i>International Journal of Obesity</i> , 2007 , 31, 1350-6	5.5	22
27	New agents in development for the management of obesity. <i>International Journal of Clinical Practice</i> , 2007 , 61, 2103-12	2.9	11
26	Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. <i>Obesity Surgery</i> , 2007 , 17, 1193-8	3.7	48
25	Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. <i>Annals of Surgery</i> , 2007 , 246, 780-5	7.8	540
24	Biliopancreatic diversion in rats is associated with intestinal hypertrophy and with increased GLP-1, GLP-2 and PYY levels. <i>Obesity Surgery</i> , 2007 , 17, 1193-1198	3.7	

23	The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients. <i>Clinical Nutrition</i> , 2006 , 25, 626-33	5.9	30
22	Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. <i>British Journal of Surgery</i> , 2006 , 93, 210-5	5.3	261
21	Attenuated peptide YY release in obese subjects is associated with reduced satiety. <i>Endocrinology</i> , 2006 , 147, 3-8	4.8	416
20	Critical role for peptide YY in protein-mediated satiation and body-weight regulation. <i>Cell Metabolism</i> , 2006 , 4, 223-33	24.6	445
19	Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. <i>Annals of Surgery</i> , 2006 , 243, 108-14	7.8	735
18	The longest-surviving patient with classical maple syrup urine disease. <i>Journal of Inherited Metabolic Disease</i> , 2006 , 29, 190-4	5.4	2
17	Characterization of ghrelin-like immunoreactivity in human plasma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2205-11	5.6	137
16	The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension. <i>Heart</i> , 2005 , 91, 241-2	5.1	32
15	Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal-weight but not obese subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 1068-71	5.6	210
14	Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 4521-4	5.6	220
13	Why do patients lose weight after Roux-en-Y gastric bypass?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 591-2	5.6	36
12	Peptide YY, appetite and food intake. <i>Proceedings of the Nutrition Society</i> , 2005 , 64, 213-6	2.9	76
11	A new antiglycolytic agent. <i>Annals of Clinical Biochemistry</i> , 2004 , 41, 43-6	2.2	9
10	Pancreatic polypeptide reduces appetite and food intake in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3989-92	5.6	375
9	Clinical authorization: what is best for the patient?. <i>Annals of Clinical Biochemistry</i> , 2003 , 40, 113-4	2.2	2
8	Free cortisol index is better than serum total cortisol in determining hypothalamic-pituitary-adrenal status in patients undergoing surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 2045-8	5.6	106
7	Inhibition of food intake in obese subjects by peptide YY3-36. <i>New England Journal of Medicine</i> , 2003 , 349, 941-8	59.2	1291
6	Oxyntomodulin suppresses appetite and reduces food intake in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 4696-701	5.6	355

5	Is a 0900-h serum cortisol useful prior to a short synacthen test in outpatient assessment?. <i>Annals of Clinical Biochemistry</i> , 2002 , 39, 148-50	2.2	56
4	Free cortisol index as a surrogate marker for serum free cortisol. <i>Annals of Clinical Biochemistry</i> , 2002 , 39, 406-8	2.2	73
3	A retrospective assessment of the effectiveness of fenofibrate 267 mg on high-density lipoprotein cholesterol levels in patients attending a lipid clinic. <i>Clinical Therapeutics</i> , 2002 , 24, 1154-60	3.5	10
2	Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery	105-116	
1	Postprandial ghrelin, cholecystokinin, peptide YY, and appetite before and after weight loss in overweight women with and without polycystic ovary syndrome		24